163 related articles for article (PubMed ID: 23494468)
41. Comparative study of propranolol hydrochloride release from matrix tablets with KollidonSR or hydroxy propyl methyl cellulose.
Sahoo J; Murthy PN; Biswal S; Sahoo SK; Mahapatra AK
AAPS PharmSciTech; 2008; 9(2):577-82. PubMed ID: 18459050
[TBL] [Abstract][Full Text] [Related]
42. Nanoparticle technology for treatment of Parkinson's disease: the role of surface phenomena in reaching the brain.
Leyva-Gómez G; Cortés H; Magaña JJ; Leyva-García N; Quintanar-Guerrero D; Florán B
Drug Discov Today; 2015 Jul; 20(7):824-37. PubMed ID: 25701281
[TBL] [Abstract][Full Text] [Related]
43. Fabrication, modeling and characterization of multi-crosslinked methacrylate copolymeric nanoparticles for oral drug delivery.
Ngwuluka NC; Pillay V; Choonara YE; Modi G; Naidoo D; du Toit LC; Kumar P; Ndesendo VM; Khan RA
Int J Mol Sci; 2011; 12(9):6194-225. PubMed ID: 22016653
[TBL] [Abstract][Full Text] [Related]
44. Interpenetrating polymer network of locust bean gum-poly (vinyl alcohol) for controlled release drug delivery.
Kaity S; Isaac J; Ghosh A
Carbohydr Polym; 2013 Apr; 94(1):456-67. PubMed ID: 23544563
[TBL] [Abstract][Full Text] [Related]
45. Report: Preparation of levodopa/carbidopa compound drug resins.
Liu H; Ding H; Zhang D; Fengsi -; Sun C
Pak J Pharm Sci; 2018 Jan; 31(1):205-211. PubMed ID: 29348105
[TBL] [Abstract][Full Text] [Related]
46. Preparation and characterization of pH-responsive guar gum microspheres.
Sharma S; Kaur J; Sharma G; Thakur KK; Chauhan GS; Chauhan K
Int J Biol Macromol; 2013 Nov; 62():636-41. PubMed ID: 24099940
[TBL] [Abstract][Full Text] [Related]
47. Blend of guar gum and Eudragit shows excellent drug release retarding behavior in sustained release tablets.
Ahmad S; Jamshaid M; Mehmood R; Bashir I; Ali R; Jameel S
Pak J Pharm Sci; 2020 Jan; 33(1):71-77. PubMed ID: 32122833
[TBL] [Abstract][Full Text] [Related]
48. Preparation of levodopa-loaded crystalsomes through thermally induced crystallization reverses functional deficits in Parkinsonian mice.
Li X; Liu Q; Zhu D; Che Y; Feng X
Biomater Sci; 2019 Mar; 7(4):1623-1631. PubMed ID: 30702723
[TBL] [Abstract][Full Text] [Related]
49. Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer.
Haupt S; Zioni T; Gati I; Kleinstern J; Rubinstein A
Eur J Pharm Sci; 2006 Jun; 28(3):204-11. PubMed ID: 16581235
[TBL] [Abstract][Full Text] [Related]
50. Guar gum oleate-graft-poly(methacrylic acid) hydrogel as a colon-specific controlled drug delivery carrier.
Seeli DS; Prabaharan M
Carbohydr Polym; 2017 Feb; 158():51-57. PubMed ID: 28024542
[TBL] [Abstract][Full Text] [Related]
51. Novel levodopa gastroretentive dosage form: in-vivo evaluation in dogs.
Klausner EA; Eyal S; Lavy E; Friedman M; Hoffman A
J Control Release; 2003 Feb; 88(1):117-26. PubMed ID: 12586509
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of polyethylene oxide compacts as gastroretentive delivery systems.
Mahalingam R; Jasti B; Birudaraj R; Stefanidis D; Killion R; Alfredson T; Anne P; Li X
AAPS PharmSciTech; 2009; 10(1):98-103. PubMed ID: 19148757
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease.
Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
Clin Neuropharmacol; 2012; 35(2):67-72. PubMed ID: 22377973
[TBL] [Abstract][Full Text] [Related]
54. Development of poly(butylene succinate) microspheres for delivery of levodopa in the treatment of Parkinson's disease.
Mohanraj K; Sethuraman S; Krishnan UM
J Biomed Mater Res B Appl Biomater; 2013 Jul; 101(5):840-7. PubMed ID: 23401377
[TBL] [Abstract][Full Text] [Related]
55. Development and characterization of mucoadhesive nanosuspension of ciprofloxacin.
Jain V; Kare P; Jain D; Singh R
Acta Pol Pharm; 2011; 68(2):273-8. PubMed ID: 21485301
[TBL] [Abstract][Full Text] [Related]
56. Formulation and evaluation of gastroretentive controlled release tablets of alfuzosin hydrochloride.
Rudraswamy-Math NR; Gupta VR
Pak J Pharm Sci; 2015 Nov; 28(6):2147-52. PubMed ID: 26639508
[TBL] [Abstract][Full Text] [Related]
57. Design and in vitro and in vivo characterization of mucoadhesive matrix pellets of metformin hydrochloride for oral controlled release: a technical note.
Ige PP; Gattani SG
Arch Pharm Res; 2012 Mar; 35(3):487-98. PubMed ID: 22477196
[TBL] [Abstract][Full Text] [Related]
58. l-Alanine induced thermally stable self-healing guar gum hydrogel as potential drug vehicle for sustained release of hydrophilic drug.
Sharma S; Afgan S; Deepak ; Kumar A; Kumar R
Mater Sci Eng C Mater Biol Appl; 2019 Jun; 99():1384-1391. PubMed ID: 30889672
[TBL] [Abstract][Full Text] [Related]
59. Novel Approaches to Optimization of Levodopa Therapy for Parkinson's Disease.
Kianirad Y; Simuni T
Curr Neurol Neurosci Rep; 2016 Apr; 16(4):34. PubMed ID: 26898686
[TBL] [Abstract][Full Text] [Related]
60. L-Dopa release from mesoporous silica nanoparticles engineered through the concept of drug-structure-directing agents for Parkinson's disease.
Morales V; McConnell J; Pérez-Garnes M; Almendro N; Sanz R; García-Muñoz RA
J Mater Chem B; 2021 May; 9(20):4178-4189. PubMed ID: 33989370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
